Hyperspectral Imaging Shows Promise in Solving Diagnostic Dilemmas in Pathology
ChemImage to Present Findings at the International Conference on Raman Spectroscopy
PITTSBURGH — Raman molecular imaging (RMI), a form of hyperspectral imaging, shows promise in identifying cancers that are typically difficult to diagnose. Its history, successes and current advancements will be discussed at the International Conference on Raman Spectroscopy (ICORS), Aug. 13 from 8:30 – 10:00 a.m. at the Boston Park Plaza Hotel in Boston.
Presented by Shona Stewart, Ph.D., senior scientist at ChemImage, “Advancing Raman Molecular Imaging for Disease Diagnosis” will discuss application of RMI in histopatholgy settings.
“As RMI is still an evolving technology, we’re looking forward to sharing this important work with an international group of our peers and gaining some valuable feedback,” said Dr. John Maier, Vice President of Biomedical Research at ChemImage.
RMI combines image information familiar to clinicians with spectral data in each pixel to imprint a digital molecular stain, unique to each sample, without the use of reagents. Images are acquired from tissue samples illuminated by a laser in a microscope and then analyzed by chemometric-based classification algorithms.
So far, RMI has shown great success in differentiating disease states in tissue, especially from the kidney and prostate. ChemImage continues to conduct and present RMI research on how it can:
• Discriminate between two challenging kidney disease diagnoses: oncocytoma, a benign condition and chromophobe renal cell carcinoma, a malignant one.
• Predict progression in prostate cancer, where slow-growing prostate cancer is difficult to differentiate from more aggressive forms.
For more information on RMI’s role in pathology, visit http://www.chemimage.com/AP. If your organization would like to participate in future RMI research studies, contact John Maier at firstname.lastname@example.org.
ChemImage Corporation, a leader in Hyperspectral Imaging technology (including Chemical and Molecular Imaging), provides instrumentation, software, contract services and expert consulting to government, industrial and academic organizations. The company’s proprietary, state-of-the-art Hyperspectral Imaging technology has many applications, including defense, security, pharmaceuticals, forensics and biomedical diagnostic research, which can reveal critical chemical and biological information from a variety of material systems.
ChemImage’s headquarters is located in Pittsburgh, Pennsylvania, where it houses research and development laboratories, as well as engineering and manufacturing facilities.
- Contact Information
- Suzanne Cibotti
- Sr. Marketing Communications Specialist
- ChemImage Corporation
- Contact via E-mail
This news content may be integrated into any legitimate news gathering and publishing effort. Linking is permitted.
News Release Distribution and Press Release Distribution Services Provided by WebWire.